Headquarters: Redwood City, CA
Founded: 2011
menlotherapeutics.com
Menlo Therapeutics reports Phase 2 Trial of Serlopitant did not meet primary end-point
- announced top-line results from MTI-103, the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis.
- The study did not meet its primary or key secondary efficacy endpoints with no statistically significant difference demonstrated between the serlopitant treated groups and the placebo treated group.
- Numerical differences favoring the serlopitant treated group were evident at all timepoints.
- Serlopitant was well-tolerated in this study.
No comments:
Post a Comment